Brand product · Semaglutide
Ozempic: FDA Status, Uses, Safety and Cost
Single receptor target (GLP-1)
What Ozempic is
Ozempic is Novo Nordisk’s brand of semaglutide approved for type 2 diabetes — NOT for weight management. Although widely discussed as a weight-loss drug, weight management is not an FDA-approved use of Ozempic; the same active ingredient is approved for weight management under the brand Wegovy, at different dose strengths.
Key facts
| Generic (active ingredient) | Semaglutide |
|---|---|
| Brand names | Ozempic |
| Drug class | GLP-1 receptor agonist |
| Manufacturer | Novo Nordisk |
| FDA status | FDA Approved for a Different IndicationNot approved for weight management |
| Administration | Subcutaneous injection (prefilled pen) |
| Frequency | Once weekly |
| Approval date | December 2017 |
| Prescription required | Yes |
| Official label | Prescribing information (DailyMed) |
What Ozempic is approved for
- Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes
- Reduction of risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease
- Reduction of risk of kidney disease progression and cardiovascular death in adults with type 2 diabetes and chronic kidney disease
Not approved for weight management
Ozempic is FDA approved, but weight management is not among its approved indications. Prescribing it for weight loss is off-label — a decision between a patient and their clinician — and insurers generally do not cover it for that purpose.
How Ozempic works
Semaglutide mimics the GLP-1 hormone, stimulating insulin release when blood sugar is high, reducing glucagon, slowing stomach emptying, and acting on appetite pathways.
- 1
Medication binds
A GLP-1 receptor agonist activates the receptor for the natural GLP-1 hormone.
- 2
Signals are sent
Appetite-regulating areas of the brain are affected, increasing fullness.
- 3
Stomach slows
Gastric emptying slows, so food stays in the stomach longer.
- 4
Intake falls
Per FDA labeling, weight reduction happens mainly through eating fewer calories.
Administration
Ozempic is given by subcutaneous injection (prefilled pen), once weekly.
We do not publish dosing guidance
Dose selection, titration schedules, and what to do about a missed dose are individual clinical decisions. Follow the instructions from your prescriber and the official prescribing information — never a website.
Important safety information
Boxed Warning — the FDA’s most serious warning
Risk of thyroid C-cell tumors: caused thyroid C-cell tumors in rodents at clinically relevant exposures; it is unknown whether this occurs in humans. Contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Summarized from the product’s FDA prescribing information. Read the full label, linked in Sources below.
Contraindications (who should not take it)
- Personal or family history of medullary thyroid carcinoma (MTC)
- Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- Known serious hypersensitivity to semaglutide or product components
Summarized from the FDA prescribing information. This is not the complete list — see the full label.
Common adverse reactions from official labeling
- Nausea
- Vomiting
- Diarrhea
- Abdominal pain
- Constipation
The most common adverse reactions listed in the product’s FDA prescribing information. Frequency and full adverse-reaction data are in the label.
Brand and generic relationships
Ozempic is a brand product containing the active ingredient semaglutide.
Cost and access
- Prescription only, for its approved diabetes indications.
- Novo Nordisk offers an Ozempic savings card for eligible commercially insured patients with type 2 diabetes; terms change — verify on the official site.
- Prescribing Ozempic for weight loss is "off-label" prescribing; insurers generally do not cover off-label weight-loss use.
Why we don't publish a price
List prices, savings-card amounts, and self-pay offers change frequently and vary by pharmacy, plan, and location. Any figure we printed would be wrong for many readers and stale within weeks. See our cost guide for how to get an accurate number for your own situation.
Insurance considerations
- Widely covered for type 2 diabetes, often with prior authorization confirming the diabetes diagnosis.
- Claims for weight-loss use are commonly denied because that is not an approved indication for Ozempic.
More detail: how insurance coverage works for weight-loss medication.
Comparisons
Frequently asked questions
- Is Ozempic approved for weight loss?
- No. Ozempic is FDA approved for type 2 diabetes (and related cardiovascular and kidney indications). Semaglutide is approved for chronic weight management only under the brand name Wegovy.
- Why do people talk about Ozempic for weight loss?
- Semaglutide reduces appetite and body weight, and clinicians may legally prescribe medicines off-label. But off-label use is a decision for a patient and their clinician, insurers rarely cover it for weight loss, and the weight-management-specific product is Wegovy.
Related guides
Sources
- Ozempic prescribing information (DailyMed, NIH) — DailyMed/NIH. Link last verified August 12, 2026.
- FDA: Medications containing semaglutide — FDA. Link last verified August 12, 2026.
- Ozempic official site (Novo Nordisk) — Manufacturer. Link last verified August 12, 2026.
Not medical advice. WeightLossDrugsGuide is an independent educational publisher. We are not a pharmacy, a medical provider, or a telehealth clinic, and we do not provide personalized medical recommendations or dosing guidance. Information here summarizes official FDA labeling and other primary sources and may not reflect the most recent changes. Always talk with a licensed clinician about your own situation, and read the full prescribing information for any medication.